Literature DB >> 25185577

Comprehensive analysis and selection of anthrax vaccine adsorbed immune correlates of protection in rhesus macaques.

Ligong Chen1, Jarad M Schiffer2, Shannon Dalton1, Carol L Sabourin3, Nancy A Niemuth3, Brian D Plikaytis2, Conrad P Quinn4.   

Abstract

Humoral and cell-mediated immune correlates of protection (COP) for inhalation anthrax in a rhesus macaque (Macaca mulatta) model were determined. The immunological and survival data were from 114 vaccinated and 23 control animals exposed to Bacillus anthracis spores at 12, 30, or 52 months after the first vaccination. The vaccinated animals received a 3-dose intramuscular priming series (3-i.m.) of anthrax vaccine adsorbed (AVA) (BioThrax) at 0, 1, and 6 months. The immune responses were modulated by administering a range of vaccine dilutions. Together with the vaccine dilution dose and interval between the first vaccination and challenge, each of 80 immune response variables to anthrax toxin protective antigen (PA) at every available study time point was analyzed as a potential COP by logistic regression penalized by least absolute shrinkage and selection operator (LASSO) or elastic net. The anti-PA IgG level at the last available time point before challenge (last) and lymphocyte stimulation index (SI) at months 2 and 6 were identified consistently as a COP. Anti-PA IgG levels and lethal toxin neutralization activity (TNA) at months 6 and 7 (peak) and the frequency of gamma interferon (IFN-γ)-secreting cells at month 6 also had statistically significant positive correlations with survival. The ratio of interleukin 4 (IL-4) mRNA to IFN-γ mRNA at month 6 also had a statistically significant negative correlation with survival. TNA had lower accuracy as a COP than did anti-PA IgG response. Following the 3-i.m. priming with AVA, the anti-PA IgG responses at the time of exposure or at month 7 were practicable and accurate metrics for correlating vaccine-induced immunity with protection against inhalation anthrax.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25185577      PMCID: PMC4248764          DOI: 10.1128/CVI.00469-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  29 in total

1.  A permutation test to compare receiver operating characteristic curves.

Authors:  E S Venkatraman
Journal:  Biometrics       Date:  2000-12       Impact factor: 2.571

2.  Search for correlates of protective immunity conferred by anthrax vaccine.

Authors:  S Reuveny; M D White; Y Y Adar; Y Kafri; Z Altboum; Y Gozes; D Kobiler; A Shafferman; B Velan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

3.  Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.

Authors:  Phillip R Pittman; Diana Fisher; Xiaofei Quinn; Trevor Schmader; Julio G Barrera-Oro
Journal:  Vaccine       Date:  2013-09-08       Impact factor: 3.641

4.  A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.

Authors:  Conrad P Quinn; Carol L Sabourin; Nancy A Niemuth; Han Li; Vera A Semenova; Thomas L Rudge; Heather J Mayfield; Jarad Schiffer; Robert S Mittler; Chris C Ibegbu; Jens Wrammert; Rafi Ahmed; April M Brys; Robert E Hunt; Denyse Levesque; James E Estep; Roy E Barnewall; David M Robinson; Brian D Plikaytis; Nina Marano
Journal:  Clin Vaccine Immunol       Date:  2012-08-29

5.  Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; M G Broster; J A Carman; R J Manchee; J Melling
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

6.  Regularization Paths for Generalized Linear Models via Coordinate Descent.

Authors:  Jerome Friedman; Trevor Hastie; Rob Tibshirani
Journal:  J Stat Softw       Date:  2010       Impact factor: 6.440

7.  Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers.

Authors:  B W McBride; A Mogg; J L Telfer; M S Lever; J Miller; P C Turnbull; L Baillie
Journal:  Vaccine       Date:  1998-05       Impact factor: 3.641

8.  Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults.

Authors:  Wendy A Keitel; John J Treanor; Hana M El Sahly; Thomas G Evans; Scott Kopper; Vanessa Whitlow; Cheryl Selinsky; David C Kaslow; Alain Rolland; Larry R Smith; Peggy A Lalor
Journal:  Hum Vaccin       Date:  2009-08-14

9.  Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; S H Leppla; M G Broster; C P Quinn; J Melling
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

10.  Variable selection under multiple imputation using the bootstrap in a prognostic study.

Authors:  Martijn W Heymans; Stef van Buuren; Dirk L Knol; Willem van Mechelen; Henrica C W de Vet
Journal:  BMC Med Res Methodol       Date:  2007-07-13       Impact factor: 4.615

View more
  16 in total

1.  Mechanistic Analysis of the Effect of Deamidation on the Immunogenicity of Anthrax Protective Antigen.

Authors:  Anita Verma; Miriam M Ngundi; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2016-05-06

Review 2.  The Bacillus cereus Group: Bacillus Species with Pathogenic Potential.

Authors:  Monika Ehling-Schulz; Didier Lereclus; Theresa M Koehler
Journal:  Microbiol Spectr       Date:  2019-05

3.  Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge.

Authors:  G S Sivko; G V Stark; K P Tordoff; K L Taylor; E Glaze; M VanRaden; J M Schiffer; J A Hewitt; C P Quinn; E O Nuzum
Journal:  Vaccine       Date:  2016-05-04       Impact factor: 3.641

4.  Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans.

Authors:  Conrad P Quinn; Carol L Sabourin; Jarad M Schiffer; Nancy A Niemuth; Vera A Semenova; Han Li; Thomas L Rudge; April M Brys; Robert S Mittler; Chris C Ibegbu; Jens Wrammert; Rafi Ahmed; Scott D Parker; Janiine Babcock; Wendy Keitel; Gregory A Poland; Harry L Keyserling; Hana El Sahly; Robert M Jacobson; Nina Marano; Brian D Plikaytis; Jennifer G Wright
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

5.  Cross-species prediction of human survival probabilities for accelerated anthrax vaccine absorbed (AVA) regimens and the potential for vaccine and antibiotic dose sparing.

Authors:  G V Stark; G S Sivko; M VanRaden; J Schiffer; K L Taylor; J A Hewitt; C P Quinn; E O Nuzum
Journal:  Vaccine       Date:  2016-08-22       Impact factor: 3.641

6.  Receptor-enhanced immunogenicity of anthrax protective antigen is primarily mediated by capillary morphogenesis Protein-2.

Authors:  Anita Verma; Mahtab Moayeri; Christopher P Mocca; Danielle O'Mard; Qian Ma; Stephen H Leppla; Drusilla L Burns
Journal:  Vaccine       Date:  2022-06-14       Impact factor: 4.169

Review 7.  New approaches to understanding the immune response to vaccination and infection.

Authors:  David Furman; Mark M Davis
Journal:  Vaccine       Date:  2015-07-29       Impact factor: 3.641

8.  Unique Inflammatory Mediators and Specific IgE Levels Distinguish Local from Systemic Reactions after Anthrax Vaccine Adsorbed Vaccination.

Authors:  Lori Garman; Kenneth Smith; Emily E Muns; Cathy A Velte; Christina E Spooner; Melissa E Munroe; A Darise Farris; Michael R Nelson; Renata J M Engler; Judith A James
Journal:  Clin Vaccine Immunol       Date:  2016-08-05

Review 9.  Recent developments in the understanding and use of anthrax vaccine adsorbed: achieving more with less.

Authors:  Jarad M Schiffer; Michael M McNeil; Conrad P Quinn
Journal:  Expert Rev Vaccines       Date:  2016-03-25       Impact factor: 5.683

Review 10.  Anthrax prophylaxis: recent advances and future directions.

Authors:  E Diane Williamson; Edward Hugh Dyson
Journal:  Front Microbiol       Date:  2015-09-24       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.